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Abstract. Injecting drug users (DU) are at high risk
for hepatitis C virus (HCV) and HIV infections. To
examine the prevalence and incidence of these infec-
tions over a 20-year period (1985–2005), the authors
evaluated 1276 DU from the Amsterdam Cohort
Studies who had been tested prospectively for HIV
infection and retrospectively for HCV infection. To
compare HCV and HIV incidences, a smooth trend
was assumed for both curves over calendar time. Risk
factors for HCV seroconversion were determined
using Poisson regression. Among ever-injecting DU,
the prevalence of HCV antibodies was 84.5% at study
entry, and 30.9% were co-infected with HIV. Their
yearly HCV incidence dropped from 27.5/100 person
years (PY) in the 1980s to 2/100 PY in recent years.
In multivariate analyses, ever-injecting DU who
currently injected and borrowed needles were at in-
creased risk of HCV seroconversion (incidence rate
ratio 29.9, 95% CI 12.6, 70.9) compared to ever-
injecting DU who did not currently inject. The risk of
HCV seroconversion decreased over calendar time.
The HCV incidence in ever-injecting DU was on
average 4.4 times the HIV incidence, a pattern seen
over the entire study period. The simultaneous
decline of both HCV and HIV incidence probably
results from reduced risk behavior at the population
level.
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Abbreviations: AC S = Amsterdam Cohort Studies (www.amsterdamcohortstudies.org); AIDS = Acquired
immunodeﬁciency syndrome; 95% CI = 95% conﬁdence interval; DU = Drug users (ever-injecting and never-
injecting); ELISA = Enzyme linked immunosorbent assay; HCV = Hepatitis C virus; HIV = Human
immunodeﬁciency virus; IRR = Incidence rate ratio; NEP = needle exchange program; PY = person years
Introduction
The most important mode of hepatitis C virus (HCV)
transmission is through exposure to infected blood
[1, 2]. Therefore injecting drug users (DU) are at high
risk for HCV infection. Their main route of trans-
mission is the sharing of needles or other injecting
equipment [3]. In this population, the reported pre-
valences of HCV range from 40% to 85% in Europe
and North America [1, 4–11].
Under the threat of AIDS, DU reduced their
injecting risk behavior and consequently their
incidence of HIV infection in the mid-1980s [12,
13]. However, their HCV incidence appears to be
less aﬀected by this decreased risk behavior, per-
haps because HCV is more transmissible than HIV.
This hypothesis is conﬁrmed by several studies that
show a high and stable prevalence of HCV anti-
bodies in this population [14–17]. In recent years,
we reported a high but declining HCV prevalence
among young DU in Amsterdam [18], whereas
others still report high and stable HCV incidence
among young DU who have recently started
injecting [15, 17, 19, 20].
The open and ongoing Amsterdam Cohort Studies
(ACS) among DU started in 1985, and stored serum
was retrospectively tested for HCV antibodies.
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present HCV incidence data for DU over two dec-
ades. The objectives of our study were to measure the
HCV incidence over this long period, to evaluate risk
factors associated with HCV seroconversion, and to
compare the HCV incidence to the HIV incidence in
this cohort over the same period.
Materials and methods
The ACS is an open, prospective cohort study
initiated to investigate the prevalence, incidence, and
risk factors of infections with HIV-1 and other
blood-borne and/or sexually transmitted diseases, as
well as the eﬀects of intervention [21]. The DU
cohort was initiated in 1985; recruitment is ongoing
and in recent years has been directed in particular to
young DU.
Participation in the ACS is voluntary, and in-
formed consent is obtained for every participant at
intake. ACS participants visit the Health Service of
Amsterdam every 4–6 months. At every visit, they
complete a standardized questionnaire about their
health, risk behavior, and socio-demographic situa-
tion. Questions about current behavior refer to the
period between the present and the preceding ACS
visit. Questions at baseline refer to the period since
1980 or since the start of regular use of hard drugs.
Blood is drawn for laboratory testing and storage.
Laboratory methods
To study HIV prevalence and incidence, all ACS
participants since 1985 (n = 1640) were prospec-
tively tested for HIV antibodies by enzyme linked
immunosorbent assays (ELISA), with conﬁrmation
by Western blot (since 1995: HIV Blot version 2.2,
Genelab diagnostics).
To study the HCV prevalence and incidence, all
participants with at least two visits between Decem-
ber 1985 and November 2005 (n = 1276) were ret-
rospectively tested for HCV antibodies, using the ﬁrst
sample available in each case. Third generation
ELISA tests were used to detect HCV antibodies
(AxSym HCV version 3.0; Abbott, Wiesbaden, Ger-
many). Individuals who were HCV-negative at ACS
entry were tested for HCV antibodies at their most
recent ACS visit. On ﬁnding HCV seroconversion,
samples taken in between these two visits were tested
to identify the moment of seroconversion.
Statistical analyses
The date of HCV or HIV seroconversion was esti-
mated as the midpoint between the last seronegative
and the ﬁrst seropositive ACS visit. The median
duration of the HCV seroconversion interval between
visits was 4.0 months, interquartile range (IQR) 3.7,
5.1 months. Using the Kaplan–Meier method, we
examined the time elapsed from the start of injecting
drugs to HCV seroconversion. Only HCV-negative
DU were included and they were considered to be at
risk from their start of injecting. Those who had
started injecting before ACS enrolment entered the
risk set at their date of ACS entry (i.e., left trunca-
tion). Those who did not seroconvert or who were
lost to follow-up were censored at their last ACS visit
or ultimately 1 November 2005. We stratiﬁed the
dates of starting injection into two decennia to
investigate diﬀerences in HCV-free survival according
to decade of starting injection.
Incidence rate curves were calculated by person-
time methods. Poisson regression was used to test
for the trend in HCV incidence over time and to
determine risk factors for HCV seroconversion. All
variables subject to change were treated as time-
dependent variables. Due to the relatively long time-
period between the point of infection and the
appearance of HCV antibodies [22], the most prob-
able moment of infection was assumed to have oc-
curred around the last seronegative visit. Therefore,
we assigned the risk behavior reported at that visit to
the HCV seroconversion period. However, for nine
participants who reported starting injection at
the ﬁrst HCV antibody-positive visit, we set back the
report of injecting risk factors from this visit to the
last HCV antibody-negative visit. Multivariate
models were built using forward-stepwise techniques,
and variables with a univariate p-value<0.20 were
considered as potential independent determinants. A
p-value <0.05 was considered statistically signiﬁcant
[23, 24]. Interactions in the ﬁnal model were
checked.
Variables related to general characteristics, drug
use, and sexual risk behavior were examined as po-
tential determinants of HCV seroconversion. General
characteristics included sex, body mass index, calen-
dar year of study visit, nationality, ethnicity, age,
homelessness, hospitalization, and HIV status. The
drug use variables included current injecting and the
calendar period of starting injection. For current
injectors, we also examined the frequency of injecting,
the main type of drug injected, whether they injected
mainly at home or borrowed needles, and needles
obtained through a needle exchange program (NEP).
Because there was a very strong association between
current injecting and current borrowing of needles,
we combined these two variables as follows: no cur-
rent injecting; current injecting but no current bor-
rowing of needles; current injecting and current
borrowing of needles. Sexual behavior included
having a steady sexual partner, injecting drug use of
the steady partner, having unprotected sex (with an
injecting partner), and current prostitution (women
only).
To compare the HCV and HIV incidence, we
assumed that the observed data (i.e., the number of
184new infections per year) follows a Poisson distri-
bution. We adopted a Bayesian approach. The
logarithm of the incidence over calendar time was
modeled using penalized splines. In this way, the
incidence of both HCV and HIV was allowed to
vary smoothly and nonlinearly over time [25–27]. If
the trends have the same pattern, then the diﬀer-
ence between the incidences on a logarithmic scale
is a constant.
Results
General characteristics and HCV prevalence
In total, 1640 DU have been enrolled in the ACS
since December 1985. Of these, 1259 DU met the
follow-up criteria of at least two visits before
November 2005 and also had enough stored serum to
allow HCV testing. Of these participants, 803/1259
(63.8%) were male and 937/1259 (74.5%) had a Dutch
nationality. The median age at ACS entry was
30.5 years (IQR 26.5, 35.8) (Table 1).
Of the 1259, 952 participants were ever-injectors:
DU who had ever injected drugs before entry
(n = 905) or who had started injecting drugs during
follow up (n = 47). The median age at start of
injection was 21.7 years (IQR 17.8, 26.0).
The median ACS follow-up time for ever-injectors
was 7.3 years (IQR 3.8,12.6), whereas it was 5.4 years
(IQR 2.6, 10.4) for never-injectors. In ever-injectors,
the main drugs recorded at ACS entry were a cocktail
of heroin and cocaine (40.0%), and most participants
had injected daily or more frequently in the preceding
6 months (34.0%).
Of the 1259 DU, 803 (63.8%) had HCV antibodies
at entry; of these, 30.6% (246/803) were HIV-co-in-
fected. The prevalence at entry of HCV antibodies in
ever-injectors varied from 92.9% in 1986 to 69.2% in
2001. The prevalence among never-injectors was 6.5%
over the total study period and varied from 0% to
22.2% per calendar year.
When evaluating HCV prevalence at entry by the
time elapsed since start of injection, such prevalence
was 59/99 (59.6%) for participants who had injected
for less than 2 years before entry vs. 137/164 (82.5%)
for participants who had injected for 3–5 years before
entry. Among participants with >10 years of inject-
ing drug use before ACS entry, the HCV prevalence
was 327/346 (94.5%).
Table 1. General characteristics of drug users in the Amsterdam Cohort Study
Total Ever-injecting DU Never-injecting DU
Total number of participants 1259 952 307
Median age
a (IQR) 30.5 (26.5, 35.8) 29.84 (26.0, 36.0) 30.6 (26.8, 35.7)
% Male sex 63.8 61.3 71.3
% Dutch nationality 74.7 86.0 71.0
Median duration of follow-up (IQR) 6.95 (3.56, 12.1) 7.33 (3.84, 12.6) 5.41 (2.60, 10.4)
Median age at start of injecting drugs (IQR) – 21.7 (17.8, 26.0) –
Main drugs injected (%)
a ––
Cocktail, heroin/cocaine 40.0
Heroin 12.2
Cocaine 8.9 –
Main other drugs used (%)
a ––
Cocktail, heroin/cocaine 4.4 41.0
Heroin 31.5 43.0
Cocaine 26.7 4.2
Frequency of injecting (%)– –
No current injecting 28.5
Daily 34.0
Weekly 30.7
Monthly 4.4
Number of recently borrowed needles(%)
a ––
0 44.9
1–10 7.6
>10 0.9
Unknown 46.4
% HCV-antibody positive
a 63.8 82.2 6.5
HCV seroconversions during follow-up 59 58 1
% HIV-positive
a 20.4 25.8 3.6
HIV seroconversions during follow-up 95 90 5
Ever-injecting DU: DU who had injected before ACS entry (n = 905) or started injecting during follow up (n = 47).
Current/recently: in previous 6 months.
aAt entry.
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Of the 456 DU seronegative for HCV at ACS entry,
59 seroconverted during follow-up, of whom 58 in-
jected and 1 did not. Among ever-injectors, the inci-
dence declined from 27.5/100 PY in the late 1980s to
approximately 2/100 PY in recent years (Figure 1a).
There was a signiﬁcant downward trend in HCV
incidence over calendar time (IRR 0.86 per calendar
year; 95% CI 0.82, 0.90, p<0.001) (Figure 1a).
In line with the decline of the HCV incidence, the
time since starting injection until HCV seroconver-
sion has lengthened in more recent calendar periods.
In 1980–1989, the median interval was 2.27 years
(IQR 1.2, 5.6 years), whereas in 1990–1999, the
median was 9.10 years (IQR 2.1, ¥ years) (Figure 2).
When restricting our analysis to DU who reported
injecting since the preceding visit, a higher incidence
but similar pattern was observed. In 1985–1990, the
incidence rate in this group was extremely high, be-
tween 50–80/100 PY, but it dropped to 5–10/100 PY
in 1990–1999.
Comparison of HCV and HIV incidence
Of 1276 DU, those HIV-negative at entry numbered
1013, of whom 95 (including 90 ever-injectors) sero-
converted for HIV during follow-up. The HIV inci-
dence rate among ever-injectors dropped from 8.52/
100 PY in 1986 to approximately 0 since 2000, with a
slight increase in 2005 (Figure 1b).
When the observed HCV and HIV incidence curves
and their ﬁtted smooth curves are plotted in one
graph with two scales, the curves look similar in
shape. When we plotted the diﬀerences between the
logs of the ﬁtted model, we found no convincing
evidence for a diﬀerence in pattern. The mean value
of the diﬀerences on a log-scale over the twenty years
is 1.48; hence the scale factor is estimated to be 4.4
(data not shown). The observed and ﬁtted incidence
patterns for both HCV and HIV with 95% conﬁdence
intervals are shown in Figure 1c.
Risk factors for HCV seroconversion
Time since start injecting can be seen as a proxy for
the duration of exposure time, and preliminary
analysis showed a very strong association between
time since start of injecting and the timepoint of HCV
seroconversion (IRR 0.80 per year), 95% CI 0.74,
0.86) (Table 2). Therefore, in bivariate analysis, to
adjust for variation in time from start of injecting
(and thus time of exposure), all other variables were
adjusted for time from start of injecting as a time-
updated variable.
After correction for time since starting injection,
the following risk factors were found to be signiﬁ-
cantly associated with an increased risk of HCV
seroconversion: the combined variable of current
injecting and current borrowing of needles, earlier
calendar year of visit, use of NEP, type of drugs in-
jected, frequency of injecting drug use, and earlier
decennium of starting injection (Table 2). Interest-
ingly, in univariate analysis persons were more at risk
for HCV if they had seroconverted for HIV (IRR
5.68; 95% CI: 2.27, 14.2) or were chronically
infected with HIV (IRR 3.12; 95% CI: 0.76, 12.8)
than if they were HIV-negative. The type of drugs
injected, and frequency of injection were associated
with an increased risk of HCV infection, their eﬀect is
attributable to current injecting drug use itself.
In fact, when evaluating these variables among only
DU injecting drugs within the past 6 months we
found no association between NEP use, the type of
drug injected, or injection frequency and HCV
infection.
In multivariate analysis, we found that current
injecting combined with current borrowing of needles
wasamajorriskforHCVseroconversion;theIRRwas
29.9 (95% CI: 12.6, 70.9) for current injecting and
borrowing compared to no injecting in the preceding
period. The longer the time between start of injecting
and study visit, the smaller the risk of HCV infection:
IRR0.89;95%CI:0.83,0.96)(Table 2).Calendaryear
remained signiﬁcantly associated with a decreased risk
of HCV infection when it was evaluated continuously
in the model (IRR 0.87; 95% CI: 0.82, 0.93).
Discussion
This study describes the prevalence and incidence of
HCV in a large group of DU in Amsterdam, the
Netherlands, over two decades. Findings show that
the HCV incidence dropped considerably in that
period. Interestingly, when we compared the HCV
incidence rate to the HIV incidence rate in the same
group of DU that have ever injected, the decrease was
similar for the two infections. In line with the decline
of the HCV incidence, the time from the start of
injecting drugs until HCV seroconversion is longer at
present than in the past.
To our knowledge, this is the ﬁrst study to docu-
ment among DU, over such a long period, a decline
in HCV incidence that is not only strong but also
comparable to the decline in HIV incidence. Our
ﬁnding of a decline in HCV incidence contrasts with
other studies that show a stable HCV incidence
[19, 28]. One explanation may be that those studies
analyzed the HCV incidence over a shorter time
interval, which might have been insuﬃcient to show a
signiﬁcant decline. In Baltimore, USA, a signiﬁcant
decline of the HCV incidence was found in injecting
DU followed between 1988 and 1996, but in contrast
to our study with ongoing recruitment of partici-
pants, this decline was observed in a closed cohort
study and a saturation eﬀect probably has contrib-
uted to this decline [29].
186In addition, the risk behavior of the total group of
DU included in the ACS has substantially declined
over time in Amsterdam [30]. This ﬁnding suggests
that a decline in risk behavior at the population level
has contributed to the simultaneous decline of HCV
and HIV incidence. The decreasing HCV incidence in
Amsterdam DU, as opposed to high incidences in
DU elsewhere, may likewise be partly explained by a
larger reduction in injecting risk behavior in
Amsterdam, compared to reductions elsewhere. The
Figure 1. (a, b) Observed HIV and HCV incidence curves among ever injecting DU in the ACS (1985–2005); (c) observed
and ﬁtted HCV (left y-axis) and HIV (right y-axis) incidence curves among ever injecting DU in the ACS (1985–2005).
187impact of methadone provision and NEP on this
decline of risk behavior is very important and should
be a focus of future studies. Methadone and NEP
were readily available throughout the study period,
and the median prescribed daily methadone dose in-
creased during this period. Murray et al. [31] dem-
onstrated by mathematical modeling that the level of
risk behavior determines whether HCV incidence
decreases. They calculated that if injecting risk
behavior is suﬃciently decreased (through intense
NEP and/or harm reduction strategies), then HCV
incidence will accordingly decline.
Mathematical models have additionally shown the
natural course of an epidemic might bring a decline in
the incidence of infection [32]. When a new infectious
agent enters a population, the number of infected
individuals and the incidence soon increase. There-
after, as the number of susceptibles decreases, the
chance for an infected individual to come into contact
with an uninfected individual decreases as well. When
the density of uninfected persons reaches a threshold
below which the number of susceptibles cannot sus-
tain an ongoing epidemic, incidence peaks and then
starts to decline. In this light, the decrease in HIV
incidence observed shortly after the introduction of
HIV in Amsterdam in the early 1980s was due to the
depletion of susceptibles, along with a reduction in
risk behavior. However, such depletion is less likely
to be the case for HCV, which has existed among DU
since the 1960s and possibly even before [33, 34]. This
implies that the decrease in injecting risk behavior
might have an even greater impact on HCV than on
HIV.
The contrast in study ﬁndings may be explained in
part by the HCV test used. We used third-generation
ELISA tests to measure HCV antibodies, whereas
studies from the late 1980s/early 1990s used ﬁrst- or
second-generation ELISA tests, which were more
inclined to give false positive test results [35].
The HCV prevalence among DU at ACS entry
varies between 70% and 90%, with lower prevalence
rates in recent years. This is consistent with what was
described among DU in Amsterdam in the early
1990s [28] and among recently starting injectors in
Amsterdam and elsewhere [18, 36]. The HCV preva-
lence in never-injecting DU is much lower than in
ever-injectors but still much higher than in low-risk
populations (e.g., blood donors) or the general pop-
ulations in Western countries [1, 37], household
transmission, rare sexual transmission, and reliabil-
ity/unreliability of answers given in interviews may
contribute to this ﬁnding among never-injecting DU.
Among DU in Amsterdam who have injected in
the past 6 months, incidence rates were extremely
high in the 1980s (50–80/100 PY). Similarly high
incidence rates have been described by Smyth et al.
among young, DU who have recently started inject-
ing in Ireland, in the 1990s [10].
A possible limitation of our study is its lack of
conﬁrmatory testing for positive results of HCV
antibody testing. However, such results in a high-risk
population are likely to be true positives [35], and
232/803 (28.9%) of the positive participants were
tested at two study visits or more, all with consistent
HCV-positive test results. Therefore we believe the
lack of conﬁrmatory testing did not inﬂuence our
results. Furthermore, although the ACS is an open,
prospective cohort study, the inﬂux of new partici-
pants in recent years has been lower than in earlier
years. Lower risk DU could be overrepresented due
to the decease of high-risk DU. However, the most
recent HCV seroconversions took place in young DU
who entered the cohort after 1994.
Our risk factor analysis showed that HCV sero-
conversion is associated not only with current
injecting and borrowing needles, as expected, but also
with calendar year and time since start of injecting.
The majority (70%) of HCV infections could have
been prevented by eliminating the borrowing of
needles. This might partly reﬂect the eﬀect of the use
of NEP, which were always available during the
study period, but individual factors also might play a
role in the decision to use NEP.
In conclusion, HCV incidence in our cohort
showed a sharp decline in the past two decades,
similar to the decline in HIV incidence, most likely
due to a decrease in injecting risk behavior. We found
that those who started injecting in a recent calendar
period are at lower risk of HCV infection, presum-
ably due to prevention activities. Thus it is important
to continue and enhance such activities among DU
and others at risk of starting injection, especially
because the HCV risk is highest just after the start of
injecting, when probably injectors are inexperienced.
Although we did not ﬁnd an independent eﬀect
from either participation in a methadone program or
Figure 2. Kaplan–Meier estimates of the cumulative pro-
portion of DU who remain without HCV infection since
starting injection, grouped per decennium: the 1980s (lower
line) and 1990s (upper line). Curves were truncated when
fewer than 10 persons remained at risk for HCV (thin line).
Persons who started injecting before 1980 or after 2000 are
not depicted in this ﬁgure, because at any moment in those
periods, less than 10 persons were at risk for HCV.
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190from the use of NEP, these prevention measures in
combination are likely to have contributed to the
decline in risk behavior related to drug use at the
population level. Therefore, it is important to evalu-
ate the possibilities for harm reduction worldwide.
During the late 1980s many acute HCV infections
occured, so there might have been more DU with
high HCV RNA levels associated with acute HCV
infection. Therefore, in that period there may have
been more and/or easier transmission of HCV.
Higher HCV RNA levels have also been associated
with HIV co-infection [38]. However, we believe that
because the HCV prevalence remained relatively high
and the pattern of the HIV and HCV incidence was
comparable during the study period, on population
level the HCV RNA level varied only little over time,
also because treatment prescription for HCV was
very limited in our cohort.
Finally, it is important to decrease the prevalence
of chronic HCV carriers and thus reduce the possi-
bility for HCV transmission. DU should therefore be
systematically screened for HCV infection, and those
chronically infected should be treated [39].
Acknowledgments
The authors would like to thank J. Bax and A.
Snuverink for data collection and blood sampling; all
subjects for study participation; M. Xiridou for her
contribution to the manuscript, and L. Phillips for
the editing of the manuscript. Financial support:
The ACS Amsterdam Cohort Studies on HIV infec-
tion and AIDS, a collaboration between the
Amsterdam Health Service, the Academic Medical
Center of the University of Amsterdam, Sanquin
Blood Supply Foundation and the University Medi-
cal Center Utrecht, are part of the Netherlands HIV
Monitoring Foundation and ﬁnancially supported by
the Netherlands National Institute for Public Health
and the Environment.
References
1. Memon MI, Memon MA. Hepatitis C: An epidemio-
logical review. J Viral Hepat. 2002; 9: 84–100.
2. van der Poel CL , Reesink HW, et al. Anti-hepatitis C
antibodies and non-A, non-B post-transfusion hepatitis
in The Netherlands. Lancet 1989; 2: 297–298.
3. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin
JS, Alexander ER. Sharing of drug preparation
equipment as a risk factor for hepatitis C. Am J Public
Health 2001; 91: 42–46.
4. Des Jarlais D, Diaz T, Perlis T, et al. Variability in the
incidence of human immunodeﬁciency virus, hepatitis
B virus, and hepatitis C virus infection among young
injecting drug users in New York City. Am J Epidemiol
2003; 157: 467–471.
T
a
b
l
e
2
.
C
o
n
t
i
n
u
e
d
U
n
i
v
a
r
i
a
t
e
a
n
a
l
y
s
i
s
B
i
v
a
r
i
a
t
e
a
n
a
l
y
s
i
s
*
M
u
l
t
i
v
a
r
i
a
t
e
a
n
a
l
y
s
i
s
H
C
V
s
c
P
Y
I
n
c
i
d
e
n
c
e
r
a
t
e
(
p
e
r
1
0
0
P
Y
)
I
R
R
9
5
%
C
l
p
V
a
l
u
e
I
R
R
9
5
%
C
l
p
V
a
l
u
e
I
R
R
9
5
%
C
l
p
V
a
l
u
e
C
u
r
r
e
n
t
i
n
j
e
c
t
i
n
g
a
n
d
b
o
r
r
o
w
i
n
g
n
e
e
d
l
e
s
N
o
c
u
r
r
e
n
t
i
n
j
e
c
t
i
n
g
1
0
6
2
3
1
.
6
1
1
<
0
.
0
0
1
1
<
0
.
0
0
1
1
<
0
.
0
0
1
C
u
r
r
e
n
t
i
n
j
e
c
t
i
n
g
,
n
o
c
u
r
r
e
n
t
b
o
r
r
o
w
i
n
g
o
f
n
e
e
d
l
e
s
2
5
1
5
9
1
5
.
7
9
.
8
0
(
4
.
7
1
,
2
0
.
4
)
6
.
2
6
(
2
.
9
4
,
1
3
.
3
)
8
.
7
0
(
4
.
0
3
,
1
8
.
8
)
C
u
r
r
e
n
t
i
n
j
e
c
t
i
n
g
a
n
d
c
u
r
r
e
n
t
b
o
r
r
o
w
i
n
g
o
f
n
e
e
d
l
e
s
1
2
2
3
5
2
.
2
3
2
.
7
(
1
4
.
1
,
7
5
.
7
)
2
1
.
4
(
9
.
1
7
,
5
0
.
1
)
2
9
.
9
(
1
2
.
6
,
7
0
.
9
)
T
i
m
e
s
i
n
c
e
s
t
a
r
t
o
f
i
n
j
e
c
t
i
n
g
5
8
8
5
6
6
.
8
0
.
8
0
(
0
.
7
4
,
0
.
8
6
)
<
0
.
0
0
1
0
.
8
9
(
0
.
8
3
,
0
.
9
6
)
<
0
.
0
0
1
Y
e
a
r
o
f
v
i
s
i
t
5
8
8
5
6
6
.
8
0
.
8
6
(
0
.
8
2
,
0
.
9
0
)
<
0
.
0
0
1
0
.
9
4
(
0
.
8
9
,
0
.
9
9
)
0
.
0
0
9
0
.
8
7
(
0
.
8
2
,
0
.
9
3
)
<
0
.
0
0
1
S
e
x
M
a
l
e
3
2
5
6
6
5
.
6
5
1
0
.
0
8
5
1
0
.
3
6
F
e
m
a
l
e
2
6
2
9
0
8
.
9
7
1
.
5
9
(
0
.
9
5
,
2
.
6
6
)
1
.
2
8
(
0
.
7
6
,
2
.
1
6
)
*
A
d
j
u
s
t
e
d
f
o
r
t
i
m
e
s
i
n
c
e
s
t
a
r
t
o
f
i
n
j
e
c
t
i
o
n
.
*
*
A
n
a
l
y
s
e
s
w
e
r
e
n
o
t
a
d
j
u
s
t
e
d
f
o
r
t
i
m
e
s
i
n
c
e
s
t
a
r
t
o
f
i
n
j
e
c
t
i
o
n
a
n
d
d
e
c
e
n
n
i
u
m
o
f
s
t
a
r
t
,
b
e
c
a
u
s
e
t
h
e
d
e
c
e
n
n
i
u
m
c
a
n
b
e
d
e
r
i
v
e
d
f
r
o
m
t
h
e
t
i
m
e
s
i
n
c
e
s
t
a
r
t
o
f
i
n
j
e
c
t
i
o
n
a
n
d
c
a
l
e
n
d
a
r
y
e
a
r
o
f
v
i
s
i
t
.
1915. Goldberg D, Burns S, Taylor A, Cameron S, Harg-
reaves D, Hutchinson S. Trends in HCV prevalence
among injecting drug users in Glasgow and Edinburgh
during the era of needle/syringe exchange. Scand.J
Infect Dis 2001; 33: 457–461.
6. Hope VD, Judd A, Hickman M, et al. Prevalence of
hepatitis C among injection drug users in England and
Wales: Is harm reduction working? Am J Public Health
2001; 91: 38–42.
7. Hutchinson SJ, McIntyre PG, Molyneaux P, et al.
Prevalence of hepatitis C among injectors in Scotland
1989–2000:Declining trendsamongyounginjectorshalt
in the late 1990s. Epidemiol Infect 2002; 128: 473–477.
8. Lorvick J, Kral AH, Seal K, Gee L, Edlin BR. Preva-
lence and duration of hepatitis C among injection drug
users in San Francisco, Calif. Am J Public Health 2001;
91: 46–47.
9. McCoy CB, Metsch LR, Collado-Mesa F, et al. The
prevalence of human immunodeﬁciency virus type 1
and hepatitis C virus among injection drug users who
use high risk inner-city locales in Miami, Florida. Mem
Inst Oswaldo Cruz 2004; 99: 789–793.
10. Smyth BP, OConnor JJ, Barry J, Keenan E. Retro-
spective cohort study examining incidence of HIV and
hepatitis C infection among injecting drug users in
Dublin. J Epidemiol Community Health 2003; 57: 310–
311.
11. Steﬀen T, Blattler R, Gutzwiller F, Zwahlen M. HIV
and hepatitis virus infections among injecting drug
users in a medically controlled heroin prescription
programme. Eur J Public Health 2001; 11: 425–430.
12. van Beek I , Dwyer R, Dore GJ, Luo K, Kaldor JM.
Infection with HIV and hepatitis C virus among
injecting drug users in a prevention setting: Retro-
spective cohort study. Br Med J 1998; 317: 433–437.
13. Nelson KE, Galai N, Safaeian M, Strathdee SA,
Celentano DD, Vlahov D. Temporal trends in the
incidence of human immunodeﬁciency virus infection
and risk behavior among injection drug users in Balti-
more, Maryland, 1988–1998. Am J Epidemiol 2002;
156: 641–653.
14. Emmanuelli J, Desenclos JC. Harm reduction inter-
ventions, behaviours and associated health outcomes in
France, 1996–2003. Addiction 2005; 100: 1690–1700.
15. Fuller CM, Ompad DC, Galea S, Wu Y, Koblin B,
Vlahov D. Hepatitis C incidence–a comparison be-
tween injection and noninjection drug users in New
York City. J Urban.Health 2004; 81: 20–24.
16. Hernandez-Aguado I, Ramos-Rincon JM, Avinio MJ,
Gonzalez-Aracil J, Perez-Hoyos S, de la Hera MG.
Measures to reduce HIV infection have not been suc-
cessful to reduce the prevalence of HCV in intravenous
drug users. Eur J Epidemiol 2001; 17: 539–544.
17. Judd A, Hickman M, Jones S, et al. Incidence of hep-
atitis C virus and HIV among new injecting drug users
in London: Prospective cohort study. Br Med J 2005;
330: 24–25.
18. van de Laar TJW, Langendam MW, Bruisten SM,
et al. Changes in risk behavior and dynamics of
hepatitis C virus infections among young drug users in
Amsterdam, the Netherlands. J Med Virol 2005; 77:
509–518.
19. Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E,
Evans JL, Busch MP, Tobler LH, Phelps B, Moss AR.
Hepatitis C virus seroconversion among young injec-
tion drug users: Relationships and risks. J Infect Dis
2002; 186: 1558–1564.
20. Miller CL, Johnston C, Spittal PM, et al. Opportuni-
ties for prevention: Hepatitis C prevalence and inci-
dence in a cohort of young injection drug users.
Hepatology 2002; 36: 737–742.
21. van den Hoek JAR, Coutinho RA, van Haastrecht
HJA, van Zadelhoﬀ AW, Goudsmit J. Prevalence and
risk factors of HIV infections among drug users and
drug-using prostitutes in Amsterdam. AIDS 1988; 2:
55–60.
22. Netski DM, Mosbruger T, Depla E, et al. Humoral
immune response in acute hepatitis C virus infection.
Clin Infect Dis 2005; 41: 667–675.
23. SAS Institute, I. SAS/STAT Software: Changes
Enhancements through Release 6.12. SAS Institute,
1996.
24. SPSS Inc. SPSS for Windows, release 9.0.0. Chicago,
1998.
25. OpenBUGS. http://mathstat.helsinki.ﬁ/openbugs/. 2006.
26. Crainiceanu C, Ruppert D, Wand MP. Bayezian
analysis for penalized spline regression using win
bugs. Technical Report 1040. http://ideas.repec.org/p/
bep/jhubio/1040.html. 1–1-2004. Berkeley Electronic
Press.
27. R. Development Core Team. A language and envi-
ronment for statistical computing. Foundation for
statistical computing. I. 2005.
28. van Ameijden EJ, Van den Hoek JA, Mientjes GH,
Coutinho RA. A longitudinal study on the incidence
and transmission patterns of HIV, HBV and HCV
infection among drug users in Amsterdam. Eur J Epi-
demiol 1993; 9: 255–262.
29. Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S,
Thomas DL. Incidence and risk factors for hepatitis C
among injection drug users in Baltimore, Maryland.
J Clin Microbiol 1997; 35: 3274–3277.
30. Lindenburg CEA, Krol A, Smit C, Buster MC, Cout-
inho RA, Prins M. Decline in HIV incidence and
injecting, but not in sexual risk behaviour, seen in drug
users in Amsterdam: A 19-year prospective cohort
study. AIDS 2006; 20: 1771–1775.
31. Murray JM, Law MG, Gao Z, Kaldor JM. The im-
pact of behavioural changes on the prevalence of
human immunodeﬁciency virus and hepatitis C among
injecting drug users. Int J Epidemiol 2003; 32: 708–
714.
32. Anderson RM, May RM. Infectious Diseases of
Humans: Dynamics and Control. Oxford: Oxford
University Press, 1991.
33. Pybus OG, Charleston MA, Gupta S, Rambaut A,
Holmes EC, Harvey PH. The epidemic behavior of the
hepatitis C virus. Science 2001; 292: 2323–2325.
34. Pybus OG, Cochrane A, Holmes EC, Simmonds P. The
hepatitis C virus epidemic among injecting drug users.
Infect Genet Evol. 2005; 5: 131–139.
35. Erensoy S. Diagnosis of hepatitis C virus (HCV)
infection and laboratory monitoring of its therapy.
J Clin Virol 2001; 21: 271–281.
19236. Des Jarlais D, Perlis T, Arasteh K, et al. Reductions in
hepatitis C virus and HIV infections among injecting
drug users in New York City, 1990–2001. AIDS 2005;
19(Suppl 3): S20–S25.
37. Hutchinson SJ, Goldberg DJ, King M, et al. Hepatitis
C virus among childbearing women in Scotland: Prev-
alence, deprivation, and diagnosis. Gut 2004; 53: 593–
598.
38. Eyster ME, Fried MW, Di Bisceglie AM , Goedert
JJ. Increasing hepatitis C virus RNA levels in
hemophiliacs: Relationship to human immunodeﬁ-
ciency virus infection and liver disease. Multicenter
Hemophilia Cohort Study. Blood 1994; 84(4): 1020–
1023.
39. Sylvestre DL. Treating hepatitis C virus infection in
active substance users. Clin Infect Dis 2005; 40(Suppl
5): S321–S324.
Address for correspondence: Charlotte H. S. B. van den
Berg, Department of Research, Cluster, Infectious Dis-
eases, Health Service of Amsterdam, Nieuwe Achtergracht
100, 1018 WT, Amsterdam, The Netherlands
Phone: +31-20-5555362; Fax: +31-20-5555533
E-mail: cvdberg@ggd.amsterdam.nl
193